Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%
Cathie Wood, known for early investments in innovative companies, has added a biotech stock to her portfolio. CRISPR Therapeutics, with its gene-editing technology and recent product approval, is poised for significant growth.